Immune activation of Bio-Germanium in a randomized, double-blind, placebo-controlled clinical trial with 130 human subjects: Therapeutic opportunities from new insights

Jung Min Cho; Jisuk Chae; Sa Rang Jeong; Min Jung Moon; Dong Yeob Shin; Jong Ho Lee

doi:10.1371/journal.pone.0240358

Immune activation of Bio-Germanium in a randomized, double-blind, placebo-controlled clinical trial with 130 human subjects: Therapeutic opportunities from new insights

PLoS One. 2020 Oct 19;15(10):e0240358. doi: 10.1371/journal.pone.0240358. eCollection 2020.

Authors

Jung Min Cho^{1

2}, Jisuk Chae^{1

2}, Sa Rang Jeong^{1

2}, Min Jung Moon^{1

2}, Dong Yeob Shin³, Jong Ho Lee^{1

2}

Affiliations

¹ National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, Republic of Korea.
² Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, Republic of Korea.
³ Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

Abstract

[NCT03677921]; www.clinicaltrials.gov [KCT0002726]; https://cris.nih.go.kr.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Double-Blind Method
Female
Germanium / administration & dosage*
Germanium / immunology
Healthy Volunteers
Humans
Immunoglobulin G / metabolism*
Killer Cells, Natural / metabolism*
Leukocyte Count
Male
Middle Aged
Quality of Life
Research Design
Treatment Outcome
Tumor Necrosis Factor-alpha / metabolism*
Young Adult

Substances

Immunoglobulin G
TNF protein, human
Tumor Necrosis Factor-alpha
Germanium

Associated data

ClinicalTrials.gov/NCT03677921
CRiS/KCT0002726

Grants and funding

This work was supported by the New Drug Discovery Fund of Geranti Pharmaceutical. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.